Skip to Main Content

Paper Details

An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma.
Sci Transl Med
38
2019
ALK, ALK protein, ALK receptor, ALK wild-type and mutant patient-derived xenograft models, CDX-0125, cancer, childhood cancers, neuroblastoma, neuroblastoma cells, neuroblastomas, patient, rhabdomyosarcomas, tumor, tumor cells, wild, wild-type and mutated ALK-expressing
Author NameAffiliation
Kateryna KrytskaDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Pichai RamanDivision of Oncology and Center for Biomedical Informatics (CBMi), Children's Hospital of Philadelphia
Pichai RamanDivision of Oncology and Center for Biomedical Informatics (CBMi), Children's Hospital of Philadelphia
Daniel MartinezChildren's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania School of Medicine
Daniel MartinezChildren's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania School of Medicine
Yael P MosseDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Yael P MossePerelman School of Medicine at the University of Pennsylvania
  • 1 - 7

Datasets

Release 1.2